Strata Critical Medical, Inc.

SRTA Nasdaq SEC CIK 1779128
Follow Strata Critical Medical Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $74.1M +50.3% vs same quarter last year
Net income −$7.6M −113.3% vs same quarter last year
EPS, diluted −$0.09 −112.9% vs same quarter last year
Operating cash flow $9.5M +125.4% vs same quarter last year
Revenue by quarter
$36.4M
$35.9M
$45.1M
$49.3M
$66.8M
$67.4M
$72.5M
$74.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$100M$0$100M$200M$300MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$197.1M$41.3M
FY24$146.8M−$27.3M
FY23$225.2M−$56.1M
FY22$146.1M−$27.3M
FY21$50.5M−$40.1M
FY20$23.4M−$10.2M
FY19$31.2M−$10.8M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2520.9%−11.3%21%
FY2420.2%−15.3%−18.6%
FY2318.7%−30.3%−24.9%
FY2215.2%−36.6%−18.7%
FY2120.8%−47.7%−79.3%
FY209.9%−44.2%−43.4%
FY1915.1%−37%−34.7%
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$58.5M
FY24−$33.4M
FY23−$34.5M
FY22−$37.9M
FY21−$15.9M
FY20−$11.2M
FY19−$10.9M
Returned to shareholdersDividends paid and shares bought back
$0$100K$200K$300KFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$0
FY24$244K
FY23$0
FY22-
FY21-
FY20-
FY19-
Net margin vs the sectorMedian of Industrials companies filing with the SEC
  • Strata Critical Medical
  • Industrials median
−100%−50%0%50%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearStrata Critical MedicalIndustrials median
FY2521%2.5%
FY24−18.6%3.3%
FY23−24.9%3.7%
FY22−18.7%3.8%
FY21−79.3%3.7%
FY20−43.4%0.2%
FY19−34.7%3.8%